{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:40:11Z","timestamp":1794969611196,"version":"4.9.1"},"reference-count":36,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2022,6,3]]},"DOI":"10.1080\/14760584.2022.2061462","type":"journal-article","created":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T09:39:33Z","timestamp":1648892373000},"page":"799-810","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":48,"title":["Ensuring quality and integrity of vaccines throughout the cold chain: the role of temperature monitoring"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0868-0007","authenticated-orcid":false,"given":"Umit","family":"Kartoglu","sequence":"first","affiliation":[{"name":"President and CEO, Extensio et Progressio, Collonge-Bellerive, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ames","sequence":"additional","affiliation":[{"name":"Sensitech Life Sciences, Beverly, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"cit0001","volume-title":"State of the world\u2019s vaccines and immunization","author":"World Health Organization","year":"2009"},{"key":"cit0002","volume-title":"Thirty-third world health assembly, Geneva, 5-23 may 1980, resolutions and decisions, annexes","author":"World Health Organization","year":"1980"},{"key":"cit0003","unstructured":"World Health Organization. Global polio eradication initiative applauds WHO African region for wild polio-free certification. News Release, 25 August 2020. https:\/\/www.who.int\/news\/item\/25-08-2020-global-polio-eradication-initiative-applauds-who-african-region-for-wild-polio-free-certification"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00080-3"},{"key":"cit0005","unstructured":"Walensky RT, 16 July 2021. https:\/\/twitter.com\/CDCDirector\/status\/1416131780806119427"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.923761"},{"key":"cit0007","unstructured":"World Health Organization. Guidelines on the international packaging and shipping of vaccines. World Health Organization, 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/338012\/9789240015432eng.pdf?sequence=1&isAllowed=y. Accesssed: November 17 2021."},{"key":"cit0008","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: quality risk management: Q9. 9 November 2005. https:\/\/database.ich.org\/sites\/default\/files\/Q9%20Guideline.pdf"},{"key":"cit0009","unstructured":"United States Pharmacopeia. < 1079> Risks and mitigation strategies for the storage and transport of finished drug products (in excerpted USP-NF standards referenced in the USP COVID-19 vaccine handling toolkit). https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-impact\/covid-19\/uspnf-standards-vaccine-handling.pdf. Accessed: November 9 2021."},{"key":"cit0010","unstructured":"European Union. Good Distribution Practice of Medicinal Products for Human Use (2013\/C 68\/01). https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A52013XC1123%2801%29. Accessed November 11 2021."},{"key":"cit0011","unstructured":"World Health Organization. Temperature-controlled transport operations by road and by air. Supplement 12 to WHO technical Report Series, No. 961, 2011, Annex 9: Model guidance for the storage and transport of time- and temperature-sensitive pharma- ceutical products. May 2015. https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/guidelines\/distribution\/trs961-annex9-supp12.pdf"},{"key":"cit0012","unstructured":"Kartoglu U. Pharmaceutical and vaccine quality illustrated. Geneva: EPELA; 2016. 47. http:\/\/epela.net\/illustrated\/"},{"key":"cit0013","unstructured":"World Health Organization. Product information sheets, 2000 edition. Department of vaccines and biologicals, WHO\/V&B\/00.13 (this document is no longer electronically available)"},{"key":"cit0014","unstructured":"World Health Organization. WHO\/PQS\/E006\/IN03.1. Irreversible freeze indicator: PQS performance specifications. https:\/\/apps.who.int\/immunization_standards\/vaccine_quality\/pqs_catalogue\/catdocumentation.aspx?id_cat=35. Accessed: November 15 2021."},{"key":"cit0015","volume-title":"The book of VVM","author":"Kartoglu U","year":"2019"},{"key":"cit0016","author":"Lavenuta G","year":"1977","journal-title":"Fierce Electronics"},{"key":"cit0017","volume-title":"Parenteral Drug Association (PDA) Pharmaceutical Cold Chain Interest Group (PCCIG) Meeting","author":"Smith JM","year":"2009"},{"key":"cit0018","unstructured":"United States Pharmacopeia. General chapter <1118> \u201cmonitoring devices- time, temperature, and humidity,\u201d The U.S. Pharmacopeia Convention (Rockville, MD, 2005) (in Excerpted USP-NF Standards referenced in the USP COVID-19 Vaccine Handling Toolkit). https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/our-impact\/covid-19\/uspnf-standards-vaccine-handling.pdf. Acccessed: November 9 2021."},{"key":"cit0019","volume-title":"Ervebo, product overview [internet]","author":"WHO","year":"2021"},{"key":"cit0020","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA allows more flexible storage, transportation conditions for Pfizer-BioNTech COVID-19 vaccine. 25 February 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-allows-more-flexible-storage-transportation-conditions-pfizer"},{"key":"cit0021","unstructured":"European Medicines Agency. More flexible storage conditions for BioNTech\/Pfizer\u2019s COVID-19 vaccine. 17 May 2021. https:\/\/www.ema.europa.eu\/en\/news\/more-flexible-storage-conditions-biontechpfizers-covid-19-vaccine"},{"key":"cit0022","unstructured":"Therapeutic Goods Administration. Wider storage and transportation conditions for the Pfizer COVID-19 vaccine now approved. 8 April 2021. https:\/\/www.tga.gov.au\/media-release\/wider-storage-and-transportation-conditions-pfizer-covid-19-vaccine-now-approved"},{"key":"cit0023","unstructured":"Health Canada. Guidelines for temperature control of drug products during storage and transportation (GUI-0069). https:\/\/www.canada.ca\/content\/dam\/hc-sc\/migration\/hc-sc\/dhp-mps\/alt_formats\/pdf\/compli-conform\/gmp-bpf\/docs\/GUI-0069_V3_EN_Aug%2010.pdf. Acccessed: November 15 2021."},{"key":"cit0024","volume-title":"Rules and guidance for pharmaceutical distributors 2017 (green guide)","author":"Medicines and Healthcare Products Regulatory Agency","year":"2017","edition":"4"},{"key":"cit0025","volume-title":"Rules and guidance for pharmaceutical manufacturers and distributors 2017 (orange guide)","author":"Medicines and Healthcare Products Regulatory Agency","year":"2017","edition":"10"},{"key":"cit0026","unstructured":"United States Pharmacopeia. < 1083> Good distribution practices-supply chain integrity. 2011. https:\/\/www.uspnf.com\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/c1083.pdf. Acccessed: November 15 2021."},{"key":"cit0027","unstructured":"US Food and Drug Administration. Federal food, drug, and cosmetic act (FD&C act). US code title 21. https:\/\/www.ecfr.gov\/cgi-bin\/text-idx?SID=85f732062d36d1151565dda714602187&mc=true&tpl=\/ecfrbrowse\/Title21\/21tab_02.tpl. Acccessed: November 15 2021."},{"key":"cit0028","unstructured":"World Health Organization. Model guidance for the storage and transport of time- and temperature sensitive pharmaceutical products. In \u201cWHO Expert Committee on specifications for pharmaceutical preparations 45th report. WHO Technical Report Series. No. 961; 2011. Annex 9\u201d. Online https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44079\/WHO_TRS_961_eng.pdf"},{"key":"cit0029","unstructured":"World Health Organization. Technical supplements to WHO technical report series, no. 961, 2011. https:\/\/cdn.who.int\/media\/docs\/default-source\/medicines\/norms-and-standards\/guidelines\/distribution\/trs961-annex9introduction.pdf?sfvrsn=64f4568_2. Accessed: October 31 2021."},{"key":"cit0030","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceutical Products for Human Use. Q7 Good manufacturing practice guide for active pharmaceutical ingredients. Step 4 version. 10 November 2000. https:\/\/database.ich.org\/sites\/default\/files\/Q7%20Guideline.pdf"},{"key":"cit0031","unstructured":"International Air Transport Association. Temperature Control Regulations (TCR). 2022 TCR Online. https:\/\/www.iata.org\/en\/publications\/store\/temperature-control-regulations\/. Accessed: January 19 2022."},{"key":"cit0032","unstructured":"International Air Transport Association. Guidance for vaccine and pharmaceutical logistics and distribution. Edition 5&Last Edition, 1 June 2021. https:\/\/www.iata.org\/en\/programs\/cargo\/pharma\/vaccine-transport\/"},{"key":"cit0033","unstructured":"World Health Organization. Immunization Practices Advisory Committee (IPAC) statement on out of cold chain (OCC) and controlled temperature chain (CTC) use of vaccines. 2016. https:\/\/www.technet-21.org\/fr\/forums\/discussions\/ipac-position-statement-on-the-controlled-temperature-chain-ctc-and-the-use-of-vaccines-out-of-cold-chain-occ. Acesswed: November 22 2021."},{"key":"cit0034","volume-title":"Use of menafrivac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers. WHO\/IVB\/13.04","author":"World Health Organization","year":"2013"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.20"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.001"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2022.2061462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T18:09:14Z","timestamp":1654884554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2022.2061462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1080\/14760584.2022.2061462"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2022.2061462","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}